Eureka strikes $6M for cancer antibodies
Drug developer Eureka Therapeutics brought in $6 million in second-round financing to continue development of antibodies used to treat cancer, VentureWire reports. Harbinger Venture Management led the round, with contributions coming from Acorn Campus Ventures and Desert Spring Life Science Capital.
The Emeryville, Calif.-based company also conducts outsourced antibody research services for other firms. It previously raised $1.6 million in a 2006 first round of funding.
Next Story: Social search startup Mechanical Zoo raises $2M more
Previous Story: Cancer drug developer ChemoCentryx cancels IPO
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.